1 min read
Add as a preferred source on Google

Eli Lilly Study Finds Weight Reductions in Adolescents With Zepbound

Participants had obesity or excess weight and related health conditions.

An unmarked height rod stands beside an empty clinic chair / TokenPost.ai
An unmarked height rod stands beside an empty clinic chair / TokenPost.ai

A study of Eli Lilly’s Zepbound found weight reductions among adolescent participants.

Participants were adolescents with obesity or excess weight who had related health conditions.

The study examined Zepbound, also known as tirzepatide.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…